Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Variability in the Treatment of Elderly Patients with Stage IIIA (N2) Non–Small-Cell Lung Cancer

Variability in the Treatment of Elderly Patients with Stage IIIA (N2) Non–Small-Cell Lung... Original Atricle Variability in the Treatment of Elderly Patients with Stage  IIIA (N2) Non–Small-Cell Lung Cancer Mark F. Berry, MD,* Mathias Worni, MD, MHS,*‡ Ricardo Pietrobon MD, PhD,* Thomas A. D’Amico, MD,* and Igor Akushevich, PhD† node metastases represent approximately 10% of all patients Introduction: We evaluated treatment patterns of elderly patients diagnosed with NSCLC. Multimodality therapy with some with stage IIIA (N2) non–small-cell lung cancer (NSCLC). combination of surgical resection, chemotherapy, and radia- Methods: The use of surgery, chemotherapy, and radiation for tion therapy is the preferred approach for patients with stage patients with stage IIIA (T1-T3N2M0) NSCLC in the Surveillance, IIIA (N2) NSCLC, but the optimal management strategy has Epidemiology, and End Results–Medicare database from 2004 to not been definitively established by randomized controlled 2007 was analyzed. Treatment variability was assessed using a mul- 3–7 data. In particular, the benefit of surgery when radiation and tivariable logistic regression model that included treatment, patient, 8–10 chemotherapy have been used is unclear. Induction chemo- tumor, and census track variables. Overall survival was analyzed using therapy and radiation therapy followed by surgical resection the Kaplan–Meier approach and Cox proportional hazard models. for patients with stage IIIA disease is feasible but may only Results: The most common treatments for 2958 patients with stage http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Variability in the Treatment of Elderly Patients with Stage IIIA (N2) Non–Small-Cell Lung Cancer

Akushevich, Igor
Journal of Thoracic Oncology , Volume 8 (6) – Jun 1, 2013
Download PDF
9 pages

Loading next page...
 
/lp/wolters-kluwer-health/variability-in-the-treatment-of-elderly-patients-with-stage-iiia-n2-VRm6ywxWIX

References (53)

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e31828916aa
pmid
23571473
Publisher site
See Article on Publisher Site

Abstract

Original Atricle Variability in the Treatment of Elderly Patients with Stage  IIIA (N2) Non–Small-Cell Lung Cancer Mark F. Berry, MD,* Mathias Worni, MD, MHS,*‡ Ricardo Pietrobon MD, PhD,* Thomas A. D’Amico, MD,* and Igor Akushevich, PhD† node metastases represent approximately 10% of all patients Introduction: We evaluated treatment patterns of elderly patients diagnosed with NSCLC. Multimodality therapy with some with stage IIIA (N2) non–small-cell lung cancer (NSCLC). combination of surgical resection, chemotherapy, and radia- Methods: The use of surgery, chemotherapy, and radiation for tion therapy is the preferred approach for patients with stage patients with stage IIIA (T1-T3N2M0) NSCLC in the Surveillance, IIIA (N2) NSCLC, but the optimal management strategy has Epidemiology, and End Results–Medicare database from 2004 to not been definitively established by randomized controlled 2007 was analyzed. Treatment variability was assessed using a mul- 3–7 data. In particular, the benefit of surgery when radiation and tivariable logistic regression model that included treatment, patient, 8–10 chemotherapy have been used is unclear. Induction chemo- tumor, and census track variables. Overall survival was analyzed using therapy and radiation therapy followed by surgical resection the Kaplan–Meier approach and Cox proportional hazard models. for patients with stage IIIA disease is feasible but may only Results: The most common treatments for 2958 patients with stage

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2013

There are no references for this article.